Media / RocketVax SARS-CoV-2 vaccine should be effective regardless of the mutation occurring on the spike protein
16 March 2021
CEO of RocketVax, Dr. Vladimir Cmiljanovic, gave an interview about the development of the second-generation SARS-CoV-2 vaccine for RTS (Serbian Broadcasting Corporation).
“The first-generation vaccines are focused on one of the virus’s proteins – the so-called spike protein. They train our immune system by exposing the coronavirus spike protein to our immune cells. The so produced spike protein antibodies can then recognize the spike protein of the wild-type virus when the real virus infection occurs, and this is how our immune system is trained by that first generation of vaccines. We take another approach, which is to train our – human – immune system against all possible coronavirus proteins. This means that our vaccine should be effective regardless of the mutation occurring on the spike protein.”
Follow our LinkedIn, Instagram, and Facebook page to keep up with our progress.
22 April 2021
Watson: “A Swiss ‘Super Vaccine’ plans to save the world from COVID-19”
There is light at the end of the tunnel. Progress is being made in vaccines against SARS-CoV-2, if somewhat slowly, particularly in Switzerland. They promise a return to normality, though they are not without setbacks. The vector vaccines developed by AstraZeneca and Johnson & Johnson are under fire following cases of thrombosis in younger women. […]
21 April 2021
Dr. Vladimir Cmiljanovic, CEO of RocketVax, gave an interview to Swiss SRF 1 radio about the progress of RVX-13 – a second-generation SARS-CoV-2 vaccine: Source: SRF 1 Radio The most important differences between RVX-13, RocketVax’s SARS-CoV-2 vaccine, and the first-generation vaccines are as follows: 1. RVX-13 induces a comprehensive activation of the immune system. Unlike […]
20 April 2021
Serbian “Telegraf” is reporting about RocketVax’s SARS-CoV-2 vaccine
When the ongoing coronavirus pandemic broke out at the start of 2020, Swiss Rockets AG set itself the challenge of manufacturing a vaccine that activates multiple lines of immune system defense to combat SARS-CoV-2 most effectively. To achieve this mission, it founded the Basel-based subsidiary RocketVax AG in the summer of 2020. To start working […]
09 April 2021
CEO of RocketVax, Dr. Vladimir Cmiljanovic, explains for Kanal 5 TV Macedonia his opinion on how China has managed to control the pandemic rapidly and effectively. During the interview, Dr. Cmiljanovic also talked about the development of the second-generation SARS-CoV-2 vaccine, RVX-13, that will provide long-lasting immunity. “The first reason is that the socialist system […]
09 February 2021
Dr. Vladimir Cmiljanovic: Our Rocket Vaccine will be the one to “blow” the coronavirus away
The Rocket Vaccine against the coronavirus will be the most effective in the defense against this vicious disease because it is the only one containing the actual, synthetically generated virus. A team of experts from Switzerland, led by Dr. Vladimir Cmiljanovic, deserves credit for that invention. What is the progress of the clinical trials? When […]